Lightnews — Scholar-powered news

Nicole Casasanta, MD @ncasasanta.bsky.social · 27d

Excited to have joined Dr. Winer and Etienne to discuss medical oncology training, the future of oncology, and more! 🎙️🩺 @yalecancer.bsky.social

Yale Cancer Center @yalecancer.bsky.social · 27d

Yale Fellows Drs. Etienne Leveille + @ncasasanta.bsky.social join Dr. Eric Winer for Yale Cancer Answers to talk about the future of #cancer care and the next generation of oncologists.
🎧 Listen live on WNPR
🍎 Download Apple Podcasts
💻 Watch on YouTube

2

Nicole Casasanta, MD @ncasasanta.bsky.social · Sep 6

Yale Heme/Onc fellows riding for our patients, families, and cancer research 🧬 at the 15th annual Closer to Free Ride! 🚴🏼‍♀️💨 @ctfride.bsky.social @yalecancer.bsky.social

1 1

Nicole Casasanta, MD @ncasasanta.bsky.social · Aug 4

www.rideclosertofree.org/participants...

A fundraising page for Nicole Casasanta

Join the Closer to Free Ride on Saturday, September 6th. Register or donate at RideCloserToFree.org.

www.rideclosertofree.org

Nicole Casasanta, MD @ncasasanta.bsky.social · Aug 4

On September 6, 2025, I’ll be participating in the Closer to Free Ride to to raise funds to support cancer research and care for those who need it most - the patients, the families, and our team @yalecancer.bsky.social and Smilow Cancer Hospital Please consider donating to my ride!🚴🏻‍♀️

1

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 2

📍HER2+ T-DXd+P is likely the new 1L SOC but many questions remain in HR+ pts, QOL, & potential maintenance strategies
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 2

Amazing talk #ASCO2025 Highlights in MBC @maryamlustberg.bsky.social @yalecancer.bsky.social
📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations

1 2

Reposted by Nicole Casasanta, MD

Yale Cancer Center @yalecancer.bsky.social · Jun 2

We have great representation in this morning's #ASCO25 poster session in Hall A! Stop by and support our presenters:
Drs. Soki Kashima, Tara Sanft, Zachary Yochum, Ro Malik, @braunmdphd.bsky.social, Aarti Bhatia, @ncasasanta.bsky.social, Jing Du, and Ismail Ajjawi.
@yaleschoolofmed.bsky.social

1 4

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 2

🔹60% dc T-DXd, 21% for AEs, 11% pt decision vs T 3.4% for AEs
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 2

🚨Practice changing interim results DESTINY-Breast09 evaluating 1st Line T-DXd + P vs THP in HER2+ MBC
🔹PFS 40.7 m vs 26.9 m!
🔹PFS2 not reached vs 36.5 m
🔹 OS immature
#ASCO2025

1 1

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 2

🔸 ctDNA+ TNBC pts after NAT strong predictor of recurrence HR 9.5 CI 2.6-35 p=0.0006
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 2

Lots of buzz around TBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰
➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%

1

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 1

🔹Imbalance between lines of therapy makes interpretation challenging

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 1

Innovative SERENA-6 trial: at molecular progression switch to SERD w/ continuation of CDK4/6i in HR+ MBC improved PFS1✅
🔹PFS2 & OS not mature
🔹 Improved TTD in QOL
🔹Control group PFS still 9.2 m
🔹Awaiting data on clearance of ctDNA after switch
#ASCO2025

NEJM.org @nejm.org · Jun 1

SERENA-6 phase 3 trial: In patients with advanced breast cancer, switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection (and before disease progression) led to significantly longer progression-free survival. nej.md/4k1dRml

#ASCO25 @ascocancer.bsky.social

1

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 1

Inspirational words on positioning yourself for success by these four women physician leaders! Sharing advice with early career women in oncology. Now we have the tools for success🛠️✨#ASCO2025 @maryamlustberg.bsky.social @drgattimays.bsky.social @yalecancer.bsky.social

2 6

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 1

Looking forward to joining the research community investigating ADCs!✨ @yalecancer.bsky.social

1 1

Nicole Casasanta, MD @ncasasanta.bsky.social · Jun 1

Outstanding talk by Dr. Ian Krop on antibody drug conjugates in the era of targeted therapies. 🔬So much groundbreaking work has been done and there’s still more work to do in understanding mechanism, mechanisms of resistance, and biomarkers for response📈📌 #ASCO2025

1

Reposted by Nicole Casasanta, MD

NEJM.org @nejm.org · May 31

INAVO120 trial: In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. nej.md/3Zje7Vt

#ASCO25 @ascocancer.bsky.social

2 3 14

Reposted by Nicole Casasanta, MD

NEJM.org @nejm.org · May 31

In advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with ESR1 mutations but not in the full patient population. Full VERITAC-2 phase 3 trial results: nej.md/3ZoCL7g

#ASCO25 @ascocancer.bsky.social

5 12

Nicole Casasanta, MD @ncasasanta.bsky.social · May 31

Impressive & practice changing ASCENT-04/KEYNOTE-D19 evaluating sacituzumab go ite an + pembro vs chemo + pembro in 1st Line PDL1+ metastatic TNBC demonstrating PFS 11.2 vs 7.8 months! 🚨Much needed improvement in 1st Line metastatic TNBC #ASCO2025

Reposted by Nicole Casasanta, MD

Yale Cancer Center @yalecancer.bsky.social · May 31

Congratulations to our faculty and fellows on their awards from @conquercancer.bsky.social at #ASCO25!
(l-r) Drs. Mariya Rozenblit, @ncasasanta.bsky.social, Devora Isseroff and Benjamin Lu.
Learn more ➡️ yalecancercenter.org/news-article...
@ascocancer.bsky.social @yaleschoolofmed.bsky.social

1 2 7

Nicole Casasanta, MD @ncasasanta.bsky.social · May 31

@yalecancer.bsky.social

1

Nicole Casasanta, MD @ncasasanta.bsky.social · May 31

Great start to #ASCO2025 with Yale Cancer Center and at the @conquercancer.bsky.social
Awards Ceremony🏆 So grateful to have the opportunity to research improved biomarkers for ADC response in patients with HER2-low, HER2-ultralow, and HER2 0 breast cancer 🔬🩺

1 1 1

Nicole Casasanta, MD @ncasasanta.bsky.social · May 8

Looking forward to seeing the data for neoadjuvant T-DXd ➡️ THP in patients with high risk, locally advanced HER2+ breast cancer! 💉
Rates of ILD similar among T-DXd/THP vs ddAC-THP arms🫁

The OncoAlert Network 🚨 @oncoalert.bsky.social · May 7

NEWS FROM INDUSTRY🚨 Source AstraZeneca
DESTINY-Breast11 Update

DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen

www.astrazeneca.com/media-centre...

3 5

Reposted by Nicole Casasanta, MD

OncLive @onclive.bsky.social · Apr 21

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC #BCSM #oncology

www.onclive.com/view/sacituz...

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC

The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.

www.onclive.com

1 1

Reposted by Nicole Casasanta, MD

OncLive @onclive.bsky.social · Apr 21

T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer #BCSM #oncology

www.onclive.com/view/t-dxd-p...

T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer

Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.

www.onclive.com

1 1